Rivaroxaban

Reversal agents for the management of oral anticoagulant-associated ICH 3:40
Reversal agents for the management of oral anticoagulant-associated ICH
Ashkan Shoamanesh • 5 Jun 2023
ESOC 2023 highlights: practice changing updates in ICH and AIS 3:07
ESOC 2023 highlights: practice changing updates in ICH and AIS
Aristeidis Katsanos • 9 Jun 2023
Initiating anticoagulation after ischemic stroke: a review of the evidence 7:32
Initiating anticoagulation after ischemic stroke: a review of the evidence
Apostolos Safouris • 23 May 2023
SECRET trial: rivaroxaban for cerebral venous thrombosis 6:22
SECRET trial: rivaroxaban for cerebral venous thrombosis
Thalia Field • 25 May 2023
Conducting randomized trials in rare stroke subtypes: insights from SECRET 1:27
Conducting randomized trials in rare stroke subtypes: insights from SECRET
Thalia Field • 25 May 2023
How is oral anticoagulant-associated intracerebral hemorrhage currently managed? 4:51
How is oral anticoagulant-associated intracerebral hemorrhage currently managed?
Hanne Christensen • 21 Oct 2022
Preventing ischemic stroke in patients with atrial fibrillation treated with anticoagulants 4:06
Preventing ischemic stroke in patients with atrial fibrillation treated with anticoagulants
Edip Gurol • 2 Apr 2022
Anti-FXa anticoagulation reversal strategies: current evidence 4:46
Anti-FXa anticoagulation reversal strategies: current evidence
Thorsten Steiner • 6 May 2022
Anticoagulation reversal prior to thrombolysis 2:30
Anticoagulation reversal prior to thrombolysis
Senta Frol • 17 May 2022
The content of VJNeurology is intended for healthcare professionals